Peptide Markers for Celiac Disease Diagnosis Sensitivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic markers for celiac disease have suboptimal sensitivity, particularly for gliadin antibodies, and are limited by the requirement for tTG2 to be presented in a non-denatured state, restricting their application in certain diagnostic tests.
Innovation Solution
A peptide with specific amino acid sequences (SEQ ID NO: 2, 3, and 4) that is recognized by antibodies from celiac patients, allowing for higher sensitivity diagnostics and compatibility with both native and denatured antigen detection methods, including Western blot procedures.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional serological tests for gliadin antibodies are used, then diagnostic procedures can be performed, but the sensitivity of the tests is low (less than 80%)
Solution Approach 1:
The patent changes the antigenic parameter from conventional gliadin or native tTG2 to a specifically engineered peptide sequence (SEQ ID NO: 2, 3, or 4) that elicits stronger antibody responses in celiac patients, thereby increasing test sensitivity while maintaining diagnostic reliability
Solution Approach 2:
The patent creates a simplified copy of the tTG2 protein in the form of a peptide fragment containing the critical epitope region. This peptide copy can be produced recombinantly and used in diagnostic assays, achieving high sensitivity without requiring the complex structure of the full native protein
2Measurement precision
If tests for tTG2 antibodies are performed, then higher sensitivity is achieved, but the tTG2 antigen must be presented in a non-denatured state, limiting test method options
Solution Approach 1:
The patent extracts the critical antigenic epitope from the complex native tTG2 protein and isolates it as a standalone peptide sequence. This extracted peptide can be used in various test formats including Western blot where denaturation occurs, whereas the full native protein cannot be used in such methods
Solution Approach 2:
The patent segments the tTG2 protein into a specific peptide fragment (SEQ ID NO: 2, 3, or 4) that contains the essential antibody-binding region. This segmentation allows the antigen to be used in denatured forms while retaining immunoreactivity, enabling versatility across different diagnostic test methodologies
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide-based diagnostic assay demonstrates higher sensitivity than existing assays, enabling the identification of celiac patients not detected by conventional tests and expanding diagnostic capabilities to include denatured antigen formats.
Implementation Method 1
the peptide of the invention is specifically recognized by antibodies produced in celiac patients
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention relates to new peptides and to their use in the diagnosis of celiac disease.